Watch More Highlights

Erin Grannan, PharmD, BCOP, of The University of Texas MD Anderson Cancer Center, discusses the phase III DESTINY-Breast03 trial, which compared ado-trastuzumab deruxtecan (T-DXd) with standard-of-care trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. Of note, T-DXd demonstrated superior progression-free survival across subgroups of patients previously treated with trastuzumab and a taxane, including those with brain metastases (Abstract GS3-01).

Copyright © 2010-2021 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.